NSCLC – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Non small cell lung cancer (NSCLC)

NSCLC – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Thelansis "NSCLC - Market Outlook, Epidemiology, Market Forecast and Competitive Landscape -2020 to 2030" report delivers an in-depth understanding of the NSCLC, historical and forecasted epidemiology as well as the NSCLC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) Japan and China.

Lung Cancer Market is estimated to record a CAGR of 14.3%. Lung cancer is a deadly lung tumor classified by uncontrolled cell development in lung tissue. Non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) are the two kinds of lung cancers, with the NSCLC type estimated to account for almost 80% of the total lung cancers in the coming years.

Thelansis estimated 205,200 adults in the United States diagnosed with lung cancer in the year 2020. NSCLC is the most common type of lung cancer, accounting for 85% of all lung cancer diagnoses. The 5-year survival rate for NSCLC is 25%.

Competitive landscape of NSCLC includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

NSCLC Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

KOLs insights of NSCLC across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Read more: NSCLC – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company                         Stage

1        DS-1062a        Daiichi Sankyo, Inc.        Phase 2

2        NovoTTF-200T        NovoCure GmbH        Phase 2

3        Nivolumab        Bristol-Myers Squibb        Phase 2

4        Pembrolizumab        Merck Sharp & Dohme Corp.        Phase 3

5        REGN2810        Regeneron Pharmaceuticals        Phase 3

6        BCD-100        Biocad        Phase 3

7        Aumolertinib        Jiangsu Hansoh Pharmaceutical Co., Ltd.        Phase 3

8        MEDI4736        AstraZeneca        Phase 2

9        SCT-I10        Sinocelltech Ltd.        Phase 3

10        FL-101        Flame Biosciences        Phase 2